Epigenetics plays an important role in regulating gene expression, and can be modified by environmental factors and physiological conditions. Studying epigenetics is a promising approach to potentially improving the diagnosis, prevention and treatment of human diseases, and to providing personalized medical care. However, the role of epigenetics in the development of diseases is not clear because epigenetic markers may be both mediators and outcomes of human diseases. It is particularly complicated to study pharmacoepigenetics, as medication use may modify the epigenetic profile. To address the challenges facing pharmacoepigenetic research of human diseases, we developed a novel design to rapidly identify, contact, and recruit participants and collect specimens for longitudinal studies of pharmacoepigenetics. Using data in real-time from electronic medical record systems, we can identify patients recently start on new medications and who also have a blood test. Prior to disposal of the leftover blood by the clinical laboratory, we are able to contact and recruit these patients, enabling us to use both their leftover baseline blood sample as well as leftover specimens at future tests. With treatment-na?ve and follow-up specimens, this system is able to study both epigenetic markers associated with disease without treatment effect as well as treatment-related epigenetic changes.
References
[1]
Bird, A. Perceptions of epigenetics. Nature 2007, 447, 396–398, doi:10.1038/nature05913.
[2]
Bell, J.T.; Pai, A.A.; Pickrell, J.K.; Gaffney, D.J.; Pique-Regi, R.; Degner, J.F.; Gilad, Y.; Pritchard, J.K. DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biol. 2011, 12, R10, doi:10.1186/gb-2011-12-1-r10.
[3]
Suzuki, M.M.; Bird, A. DNA methylation landscapes: Provocative insights from epigenomics. Nat. Rev.Genet. 2008, 9, 465–476, doi:10.1038/nrg2341.
[4]
Van der Maarel, S.M. Epigenetic mechanisms in health and disease. Ann. Rheum. Dis. 2008, 67, ii97–ii100, doi:10.1136/ard.2008.098392.
Lister, R.; Pelizzola, M.; Dowen, R.H.; Hawkins, R.D.; Hon, G.; Tonti-Filippini, J.; Nery, J.R.; Lee, L.; Ye, Z.; Ngo, Q.M.; et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009, 462, 315–322, doi:10.1038/nature08514.
[7]
Stenvinkel, P.; Karimi, M.; Johansson, S.; Axelsson, J.; Suliman, M.; Lindholm, B.; Heimburger, O.; Barany, P.; Alvestrand, A.; Nordfors, L.; et al. Impact of inflammation on epigenetic DNA methylation—A novel risk factor for cardiovascular disease? J. Intern. Med. 2007, 261, 488–499, doi:10.1111/j.1365-2796.2007.01777.x.
[8]
Sun, Y.V.; Lazarus, A.; Smith, J.A.; Chuang, Y.H.; Zhao, W.; Turner, S.T.; Kardia, S.L. Gene-specific DNA methylation association with serum levels of C-reactive protein in african americans. PLoS One 2013, 8, e73480.
[9]
Teschendorff, A.E.; Menon, U.; Gentry-Maharaj, A.; Ramus, S.J.; Weisenberger, D.J.; Shen, H.; Campan, M.; Noushmehr, H.; Bell, C.G.; Maxwell, A.P.; et al. Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res. 2010, 20, 440–446, doi:10.1101/gr.103606.109.
[10]
Bocklandt, S.; Lin, W.; Sehl, M.E.; Sanchez, F.J.; Sinsheimer, J.S.; Horvath, S.; Vilain, E. Epigenetic predictor of age. PLoS One 2011, 6, e14821.
[11]
Waterland, R.A.; Jirtle, R.L. Transposable elements: Targets for early nutritional effects on epigenetic gene regulation. Mol. Cell. Biol. 2003, 23, 5293–5300, doi:10.1128/MCB.23.15.5293-5300.2003.
[12]
Ivanov, M.; Kacevska, M.; Ingelman-Sundberg, M. Epigenomics and interindividual differences in drug response. Clin. Pharmacol. Ther. 2012, 92, 727–736, doi:10.1038/clpt.2012.152.
[13]
Fraga, M.F.; Ballestar, E.; Paz, M.F.; Ropero, S.; Setien, F.; Ballestar, M.L.; Heine-Suner, D.; Cigudosa, J.C.; Urioste, M.; Benitez, J.; et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl. Acad. Sci. USA 2005, 102, 10604–10609, doi:10.1073/pnas.0500398102.
[14]
Breitling, L.P.; Yang, R.; Korn, B.; Burwinkel, B.; Brenner, H. Tobacco-smoking-related differential DNA methylation: 27K discovery and replication. Am. J. Hum. Genet. 2011, 88, 450–457, doi:10.1016/j.ajhg.2011.03.003.
[15]
Shenker, N.S.; Polidoro, S.; van Veldhoven, K.; Sacerdote, C.; Ricceri, F.; Birrell, M.A.; Belvisi, M.G.; Brown, R.; Vineis, P.; Flanagan, J.M. Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking. Hum. Mol. Genet. 2013, 22, 843–851, doi:10.1093/hmg/dds488.
[16]
Sun, Y.V.; Smith, A.K.; Conneely, K.N.; Chang, Q.; Li, W.; Lazarus, A.; Smith, J.A.; Almli, L.M.; Binder, E.B.; Klengel, T.; et al. Epigenomic association analysis identifies smoking-related DNA methylation sites in African Americans. Hum. Genet. 2013, 132, 1027–1037, doi:10.1007/s00439-013-1311-6.
[17]
Collotta, M.; Bertazzi, P.A.; Bollati, V. Epigenetics and pesticides. Toxicology 2013, 307, 35–41, doi:10.1016/j.tox.2013.01.017.
[18]
Pogribny, I.P.; Rusyn, I. Environmental toxicants, epigenetics, and cancer. Adv. Exp. Med. Biol. 2013, 754, 215–232, doi:10.1007/978-1-4419-9967-2_11.
[19]
Kohane, I.S. Using electronic health records to drive discovery in disease genomics. Nat. Rev.Genet. 2011, 12, 417–428, doi:10.1038/nrg2999.
[20]
Roden, D.M.; Pulley, J.M.; Basford, M.A.; Bernard, G.R.; Clayton, E.W.; Balser, J.R.; Masys, D.R. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin. Pharmacol. Ther. 2008, 84, 362–369, doi:10.1038/clpt.2008.89.
[21]
Denny, J.C.; Ritchie, M.D.; Basford, M.A.; Pulley, J.M.; Bastarache, L.; Brown-Gentry, K.; Wang, D.; Masys, D.R.; Roden, D.M.; Crawford, D.C. PheWAS: Demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics 2010, 26, 1205–1210, doi:10.1093/bioinformatics/btq126.
[22]
Ritchie, M.D.; Denny, J.C.; Crawford, D.C.; Ramirez, A.H.; Weiner, J.B.; Pulley, J.M.; Basford, M.A.; Brown-Gentry, K.; Balser, J.R.; Masys, D.R.; et al. Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am. J. Hum. Genet. 2010, 86, 560–572, doi:10.1016/j.ajhg.2010.03.003.
[23]
Zhou, K.; Pearson, E.R. Insights from genome-wide association studies of drug response. Annu. Rev. Pharmacol. Toxicol. 2013, 53, 299–310, doi:10.1146/annurev-pharmtox-011112-140237.
[24]
Foley, D.L.; Craig, J.M.; Morley, R.; Olsson, C.A.; Dwyer, T.; Smith, K.; Saffery, R. Prospects for epigenetic epidemiology. Am. J. Epidemiol. 2009, 169, 389–400.
Qiu, W.; Baccarelli, A.; Carey, V.J.; Boutaoui, N.; Bacherman, H.; Klanderman, B.; Rennard, S.; Agusti, A.; Anderson, W.; Lomas, D.A.; et al. Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function. Am. J. Respir. Crit. Care Med. 2012, 185, 373–381, doi:10.1164/rccm.201108-1382OC.
[27]
Liu, Y.; Aryee, M.J.; Padyukov, L.; Fallin, M.D.; Hesselberg, E.; Runarsson, A.; Reinius, L.; Acevedo, N.; Taub, M.; Ronninger, M.; et al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat. Biotechnol. 2013, 31, 142–147, doi:10.1038/nbt.2487.
[28]
Lemaire, M.; Chabot, G.G.; Raynal, N.J.; Momparler, L.F.; Hurtubise, A.; Bernstein, M.L.; Momparler, R.L. Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer. BMC Cancer 2008, 8, e128, doi:10.1186/1471-2407-8-128.
Pai, A.A.; Bell, J.T.; Marioni, J.C.; Pritchard, J.K.; Gilad, Y. A genome-wide study of DNA methylation patterns and gene expression levels in multiple human and chimpanzee tissues. PLoS Genet. 2011, 7, e1001316, doi:10.1371/journal.pgen.1001316.
[31]
Sun, Y.V.; Turner, S.T.; Smith, J.A.; Hammond, P.I.; Lazarus, A.; van de Rostyne, J.L.; Cunningham, J.M.; Kardia, S.L. Comparison of the DNA methylation profiles of human peripheral blood cells and transformed B-lymphocytes. Hum. Genet. 2010, 127, 651–658, doi:10.1007/s00439-010-0810-y.